Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-399 in advanced solid tumors / advanced NSCLC
jRCT2080225128Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of telisotuzumab vedotin in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and Pharmacokinetics. Started Mar 2020; status: completed.
02
Drugs
telisotuzumab vedotin
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225128.